Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mast Cell Disorders
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell activation syndrome besides omalizumab?
Related Questions
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
What is the overlap of POTS and Ehlers-Danlos with MCAS?
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
How do you manage atopic dermatitis in pediatric patients who has failed dupilumab?
How often do you find a food allergy on a skin test in an EoE patient that when avoided will result in significant resolution of EoE?
Do you believe that pretreatment with montelukast or other LTRAs can reduce the risk of urticaria or angioedema with NSAIDS?
What VIT would you recommend in a patient who had grade 5 anaphylaxis to a stinging insect but negative IDT and serum IgE?
